7484 Federal Register / Vol. 75, No. 33 / Friday, February 19, 2010 / Notices 

Services Administration’s (SAMHSA) 

Drug Testing Advisory Board (DTAB) 

will meet on March 8, 2010. 

The meeting is open to the public and will 

include discussion of the Mandatory 

Guidelines for Federal Workplace Drug 

Testing Programs, including implementation 

of the revised Mandatory Guidelines; Federal 

drug testing updates from the Department of 

Transportation (DOT), the Department of 

Defense, and the Nuclear Regulatory 

Commission; review of significant changes in 

the revised Mandatory Guidelines; review of 

the National Laboratory Certification Program 

planned implementation of the revised 

Mandatory Guidelines; an update on the 

revised Federal Custody and Control Form; a 

review of the special proficiency testing 

program for initial and confirmation testing 

for new analytes and new cutoffs; an update 

on instrumented initial test facilities; an 

update on the DTAB working groups; and a 

comparison of HHS and DOT urine collection 

requirements. 

DTAB members and invited presenters will 

participate in this meeting through remote 

internet connection. On-site attendance by 

the public will be limited to space available. 

The meeting can also be accessed by the 

public via teleconference. To obtain 

teleconference call-in numbers and access 

codes, to make arrangements to attend onsite, or to request special accommodations for 

persons with disabilities, please register at 

the SAMHSA Committees’ Web site at 

https://nac.samhsa.gov/Registration/ 

meetingsRegistration.aspx or communicate 

with DTAB’s Program Assistant, Ms. Giselle 

Hersh (see contact information below). 

SAMHSA would like to ensure that 

advisory committee meetings proceed in an 

orderly fashion, are conducted in a safe and 

secure environment, that the right of free 

speech is protected, and that the ability of 

SAMHSA Advisory Committees to 

accomplish their objectives is not disrupted. 

Therefore, the following procedures will be 

followed at all DTAB meetings: 

• Attendees are subject to security 

screening, including identification (driver’s 

license) review, metal detector screening, and 

inspection of briefcases, packages, etc. Each 

attendee will be issued a security badge that 

must be worn at all times while in the 

building. 

• Any interested person who wishes to be 

assured of the right to make an oral 

presentation during the Public Comment 

portion of the DTAB meeting must register 

with Ms. Hersh before the meeting. 

• Those who have not registered before the 

meeting will only be invited to speak at the 

discretion of the Chair and should submit 

their request to the Designated Federal 

Official on the day of the meeting. 

• Public Comment participants who are 

designated to speak may be questioned only 

by the Chair or DTAB members. 

• Audience members may not present 

comments or questions to DTAB members 

unless recognized by the Chair. 

• Attendees at the meeting are asked to 

maintain order and not display behavior that 

is disruptive to the meeting (i.e., shouting 

from the audience, loud outbursts). 

• We ask that attendees not approach the 

DTAB table area during the meeting without 

permission from the Chair or the Designated 

Federal Official. 

• The DTAB Chair or Designated Federal 

Official will note on the record any 

disruptive behavior and will ask the person 

to cease the behavior or else leave the 

meeting room. 

Substantive program information, a 

summary of the meeting, and a roster of 

DTAB members may be obtained as soon as 

possible after the meeting, either by accessing 

the SAMHSA Committee Web site, https:// 

www.nac.samhsa.gov/DTAB/meetings.aspx, 

or by contacting Ms. Hersh. The transcript for 

the meeting will also be available on the 

SAMHSA Committee Web site within three 

weeks after the meeting. 

Committee Name: Substance Abuse and 

Mental Health Services Administration, Drug 

Testing Advisory Board. 

Date/Time/Type: March 8, 2010 from 10 

a.m. to 4:45 p.m. EST: Open. 

Place: Sugarloaf and Seneca Conference 

Rooms, 1 Choke Cherry Road, Rockville, 

Maryland 20857. 

Contacts: 

Ms. Giselle Hersh, Program Assistant, 

SAMHSA Drug Testing Advisory Board, 1 

Choke Cherry Road, Room 2–1042, 

Rockville, Maryland 20857, Telephone: 

240–276–2600, Fax: 240–276–2610, E-mail: 

Giselle.Hersh@samhsa.hhs.gov. 

Donna M. Bush, PhD, Designated Federal 

Official, SAMHSA Drug Testing Advisory 

Board, 1 Choke Cherry Road, Room 2– 

1033, Rockville, Maryland 20857, 

Telephone: 240–276–2600, Fax: 240–276– 

2610. 

Toian Vaughn, 

Committee Management Officer, Substance 

Abuse and Mental Health Services 

Administration. 

[FR Doc. 2010–3227 Filed 2–18–10; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

General Medical Sciences Initial Review 

Group, Minority Programs Review 

Subcommittee B. 

Date: March 8–9, 2010. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Palomar—Washington, DC, 

Washington, DC 20037. 

Contact Person: Rebecca H. Johnson, PhD, 

Scientific Review Officer, Office of Scientific 

Review, National Institute of General Medical 

Sciences, National Institutes of Health, 

Natcher Building, Room 3AN18C, Bethesda, 

MD 20892, 301–594–2771, 

johnsonrh@nigms.nih.gov. 

Name of Committee: National Institute of 

General Medical Sciences Initial Review 

Group, Minority Programs Review 

Subcommittee A. 

Date: March 8, 2010. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Courtyard Marriott Chevy Chase, 

Chevy Chase, MD 20815. 

Contact Person: Mona R. Trempe, PhD, 

Scientific Review Officer, Office of Scientific 

Review, National Institute of General Medical 

Sciences, National Institutes of Health, 45 

Center Drive, Room 3AN12, Bethesda, MD 

20892, 301–594–3998, 

trempemo@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives, National 

Institutes of Health, HHS) 

Dated: February 4, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–3200 Filed 2–18–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 


pwalker on DSK8KYBLC1PROD with NOTICES